From the very start of this pandemic, addressing COVID-19 has been a top priority for CureVac.
Our mRNA technology instructs the human body to activate its own defense mechanism. To do that, we use messenger RNA (mRNA) that encodes the instruction manual cells needed to produce a specific protein. For our COVID-19 vaccine candidate, CVnCoV, we programmed the mRNA to serve as the instruction manual for the production of the spike protein, a key protein for the COVID-19 vaccine development. After receiving the vaccine, the body recognizes the protein as something potentially hostile and activates the immune system to produce antibodies and T cells to fight against it. In this way, we mimic the natural viral infection and activate the body’s defense system.
Our technology is characterized by:
Use of unmodified, natural mRNA
This allows for improved induction of the viral defenses of the body, including interferon type 1.
Ability to induce immune responses at low mRNA doses
Due to targeted mRNA optimization, our vaccine is able to induce high levels of protein production within the cells.
Induction of an immune response comparable to a natural COVID-19 infection
In the Phase 1 clinical trial, antibody responses in vaccinated participants were found to be comparable to the antibody response detected in recovered COVID-19 patients.
Improved temperature stability for standard cold chain logistics
CVnCoV remains stable and within defined specifications for at least three months when stored at a standard refrigerator temperature of +5°C (+41°F) and for up to 24 hours as ready-to-use vaccine when stored at room temperature.
